NCT07647666

Brief Summary

Stroke-associated pneumonia is a common and clinically important complication after acute ischemic stroke, especially in non-intubated patients with impaired consciousness and reduced cough or swallowing reflexes. Conventional oral or nasal suction may be insufficient for removing deep oropharyngeal secretions. This prospective randomized controlled trial will evaluate whether a patented oropharyngeal flushing suction tube combined with direct laryngoscopy reduces the 28-day incidence of stroke-associated pneumonia compared with laryngoscope-guided standard suction and conventional oral/nasal suction.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
120

participants targeted

Target at P50-P75 for not_applicable

Timeline
37mo left

Started Aug 2026

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 10, 2026

Completed
5 days until next milestone

First Posted

Study publicly available on registry

June 15, 2026

Completed
2 months until next milestone

Study Start

First participant enrolled

August 1, 2026

Expected
2.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2029

1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

July 31, 2029

Last Updated

June 15, 2026

Status Verified

June 1, 2026

Enrollment Period

2.9 years

First QC Date

June 10, 2026

Last Update Submit

June 10, 2026

Conditions

Keywords

Oropharyngeal SuctionLaryngoscopeAirway ManagementSuction TubeAspiration Pneumonia

Outcome Measures

Primary Outcomes (1)

  • Incidence of Stroke-Associated Pneumonia Within 28 Days

    Proportion of participants who meet diagnostic criteria for stroke-associated pneumonia within 28 days after enrollment, adjudicated by blinded outcome assessors using clinical findings, laboratory data, and serial chest imaging.

    Within 28 days after enrollment

Secondary Outcomes (5)

  • 28-Day All-Cause Mortality

    28 days after enrollment

  • Artificial Airway Establishment or Invasive Mechanical Ventilation

    Within 28 days after enrollment

  • Longitudinal Inflammatory Biomarker Trajectories

    Day 0 and Days 3, 7, 10, 14, 18, and 21

  • Pathogen Distribution and Multidrug-Resistant Organism Detection

    On the day of suspected stroke-associated pneumonia and Days 5 and 14 after suspicion

  • Procedure-Related Adverse Events

    During each procedure and within 28 days after enrollment

Study Arms (3)

Oropharyngeal Flushing Suction Tube Plus Laryngoscope

EXPERIMENTAL

Participants receive standard stroke care and routine oral care plus direct laryngoscope-guided suction using the oropharyngeal flushing suction tube. Sterile saline irrigation of approximately 5 mL may be delivered through the irrigation lumen with simultaneous suction when secretions are tenacious.

Device: Oropharyngeal Flushing Suction TubeProcedure: Laryngoscope-Guided Oropharyngeal Suction

Standard Suction Tube Plus Laryngoscope

ACTIVE COMPARATOR

Participants receive standard stroke care and routine oral care plus direct laryngoscope-guided suction using a standard single-lumen suction catheter. No oropharyngeal flushing suction tube is used.

Procedure: Laryngoscope-Guided Oropharyngeal SuctionDevice: Standard Suction Catheter

Conventional Oral or Nasal Suction

ACTIVE COMPARATOR

Participants receive standard stroke care and routine oral care plus conventional blind oral and/or nasal suction using a standard suction catheter. No laryngoscope and no flushing suction tube are used.

Procedure: Conventional Oral or Nasal Suction

Interventions

A patented single-use dual-lumen suction tube designed for simultaneous irrigation and suction of oropharyngeal and deep pharyngeal secretions under direct laryngoscopic visualization. The device includes separate irrigation and suction lumens and allows sterile saline irrigation with simultaneous suction when secretions are tenacious.

Oropharyngeal Flushing Suction Tube Plus Laryngoscope

Direct laryngoscopy is used to visualize the oropharyngeal and glottic area and guide targeted suctioning of oropharyngeal and deep pharyngeal secretions.

Oropharyngeal Flushing Suction Tube Plus LaryngoscopeStandard Suction Tube Plus Laryngoscope

A conventional single-lumen suction catheter used for oropharyngeal or airway secretion suctioning according to routine clinical practice.

Standard Suction Tube Plus Laryngoscope

Blind oral and/or nasal suctioning performed with a standard suction catheter according to routine clinical practice, without direct laryngoscopic visualization and without use of the oropharyngeal flushing suction tube.

Conventional Oral or Nasal Suction

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Confirmed acute ischemic stroke by cranial CT or MRI.
  • Age 18 years or older.
  • Glasgow Coma Scale score of 6 to 12.
  • No artificial airway and no requirement for invasive mechanical ventilation at enrollment.
  • Written informed consent provided by the participant or legally authorized representative.

You may not qualify if:

  • Existing artificial airway or invasive mechanical ventilation at ICU admission or screening.
  • Pre-existing pulmonary infection at enrollment, or definite extra-pulmonary organ or tissue infection during the study period.
  • Hemorrhagic blood disorder, clinically significant coagulopathy, or bleeding risk precluding laryngoscopy.
  • Oral or maxillofacial deformity impeding laryngoscope insertion.
  • Cervical spine fracture, atlantoaxial instability, or other condition restricting neck extension or movement.
  • Confirmed or suspected pregnancy.
  • Irreversible critical illness with anticipated survival less than 28 days.
  • Uncontrolled hypertension or recurrent malignant arrhythmias.
  • Other conditions judged by investigators to make participation unsuitable.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Pudong Gongli Hospital, Shanghai University of Medicine & Health Sciences

Shanghai, Shanghai Municipality, 200135, China

Location

MeSH Terms

Conditions

Ischemic StrokePneumonia, Aspiration

Interventions

Congresses as Topic

Condition Hierarchy (Ancestors)

StrokeCerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesVascular DiseasesCardiovascular DiseasesPneumoniaRespiratory Tract InfectionsInfectionsLung DiseasesRespiratory Tract Diseases

Intervention Hierarchy (Ancestors)

OrganizationsHealth Care Economics and Organizations

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Masking Details
Due to the nature of the procedural and device intervention, participants' bedside care providers and operators cannot be blinded. Stroke-associated pneumonia diagnosis and adverse event classification will be performed by independent outcome assessors blinded to group allocation.
Purpose
PREVENTION
Intervention Model
PARALLEL
Model Details: Participants will be randomized in a 1:1:1 ratio to three parallel groups: oropharyngeal flushing suction tube plus laryngoscope, standard suction tube plus laryngoscope, or conventional oral/nasal suction.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

June 10, 2026

First Posted

June 15, 2026

Study Start (Estimated)

August 1, 2026

Primary Completion (Estimated)

June 30, 2029

Study Completion (Estimated)

July 31, 2029

Last Updated

June 15, 2026

Record last verified: 2026-06

Data Sharing

IPD Sharing
Will not share

Identifiable or raw individual participant data will not be publicly shared. After publication of the primary results, de-identified data may be made available to qualified researchers upon reasonable written request, subject to ethics committee approval and a data-sharing agreement.

Locations